Investigating the role of DCAF15 in Acute Myeloid Leukemia
Assessment of DCAF15 role in Acute Myeloid Leukemia
This study is looking at how a protein called DCAF15 affects the growth of Acute Myeloid Leukemia (AML) and hopes to find new ways to treat it, which could help patients understand their cancer better and explore new treatment options.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11130434 on NIH RePORTER |
What this research studies
This research focuses on understanding how DCAF15, an E3 ligase, influences the progression of Acute Myeloid Leukemia (AML) by regulating the degradation of specific proteins involved in genome organization. By examining the genetic alterations in AML and the role of the ubiquitin pathway, the study aims to uncover new therapeutic targets that could improve treatment outcomes. Patients may benefit from insights into how their cancer develops and potential new treatment options that arise from this research.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Acute Myeloid Leukemia who may benefit from new treatment strategies targeting the ubiquitin pathway.
Not a fit: Patients with other types of leukemia or hematologic malignancies unrelated to the mechanisms being studied may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to innovative therapies that significantly improve survival rates for patients with Acute Myeloid Leukemia.
How similar studies have performed: Previous research has shown promising results in targeting the ubiquitin pathway for cancer treatment, indicating that this approach may lead to significant advancements in AML therapy.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Busino, Luca — University of Pennsylvania
- Study coordinator: Busino, Luca
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.